# Deb Kemper

> Deb Kemper is a seed investor at Golden Seeds (Boston) backing B2B and PaaS. See 2 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Golden Seeds](https://shizune.co/investors/profile/golden-seeds)
- Location: Boston, United States
- Total investments: 2
- Last investment: Feb 2024
- Lead investor: 50%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/debkemper/
- X (Twitter): https://twitter.com/Deb_Kemper

Deb Kemper is a General Partner at Golden Seeds Venture Fund. She previously was the Boston Chair for Golden Seeds Angel Group. She is an active early-stage investor via Libra Global Partners, mentor to entrepreneurs, and board member. Prior to Golden Seeds, Deb was a management consultant at McKinsey & Company where she served clients inthe healthcare, energy, electronics and consumer products sectors. Deb earned an MBA from The Tuck School of Business at Dartmouth where she was a Tuck Scholar. She completed her BS in Engineering from Cornell University where she graduated With Distinction.

## Contacts

5 contacts available for Deb Kemper: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/deb-kemper?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| B2B | 1 | 50% |
| PaaS | 1 | 50% |
| SaaS | 1 | 50% |
| Internet | 1 | 50% |
| Software | 1 | 50% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Strategikon Pharma | Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipelinespending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement. | $7M | Series A | Feb 06, 2024 | https://strategikonpharma.com/ |
| Performlive | PerformLive is a purpose-driven community for Creators & Sellers to monetize their talent and products via interactive live stream. It combines the power of live interaction, augmented reality, social selling & live commerce, all in one platform. | $740.1K | Seed | Oct 30, 2020 | https://www.performlive.live |

2 of 2 investments shown.

## Co-investors
- [37 Angels](https://shizune.co/investors/profile/37-angels) — VC Fund, 2 deals together
- [Debiopharm Innovation Fund](https://shizune.co/investors/profile/debiopharm-innovation-fund) — VC Fund, 1 deal together
- [Golden Seeds Venture Fund](https://shizune.co/investors/profile/golden-seeds-venture-fund) — VC Fund, 1 deal together
- [HearstLab](https://shizune.co/investors/profile/hearstlab-36b3) — VC Fund, 1 deal together
- [Next Act Fund](https://shizune.co/investors/profile/next-act-fund) — VC Fund, 1 deal together
- [Osage Venture Partners](https://shizune.co/investors/profile/osage-partners) — VC Fund, 1 deal together

## About Golden Seeds

VC Fund · New York, United States

Golden Seeds is a seed-stage investment firm with a focus on women leaders. Their investment thesis rests on the extensive research that concludes that gender-diverse teams produce a better return on equity. By seeking companies where women hold leadership positions and own substantial equity, they are funding companies that are likely to havediverse perspectives that will contribute to success.

5 contacts available at Golden Seeds.

| Name | Title | Profile |
| --- | --- | --- |
| Jo Ann Corkran | Managing Partner | https://shizune.co/investors/profile/jo-ann-corkran |
| Ulya Khan | Managing Director | https://shizune.co/investors/profile/ulya-khan |
| Carolyn Fikke | Managing Director | https://shizune.co/investors/profile/carolyn-fikke |
| Charles Follini | Early Stage Investor & Board Member | https://shizune.co/investors/profile/cj-follini |
| Danna Redmond | Managing Director | https://shizune.co/investors/profile/danna-redmond |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

## FAQ

### What does Deb Kemper invest in?

Deb Kemper invests primarily in B2B, PaaS and SaaS startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Deb Kemper?

Public channels for Deb Kemper include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Deb Kemper last invest?

The most recent investment recorded for Deb Kemper closed in Feb 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co